Ken Griffin Inmune Bio, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$4.86 - $9.86 $82,134 - $166,634	16,900 Added 136.29%	29,300 $157,000
Q2 2024 Aug 14, 2024	SELL	$7.15 - $11.84 $64,350 - $106,560	-9,000 Reduced 42.06%	12,400 $109,000
Q1 2024 May 15, 2024	BUY	$10.53 - $14.01 $132,678 - $176,526	12,600 Added 143.18%	21,400 $251,000
Q4 2023 Feb 14, 2024	SELL	$6.6 - $11.52 $8,580 - $14,976	-1,300 Reduced 12.87%	8,800 $99,000
Q3 2023 Nov 14, 2023	SELL	$6.61 - $10.9 $17,847 - $29,430	-2,700 Reduced 21.09%	10,100 $68,000
Q2 2023 Aug 14, 2023	SELL	$6.5 - $10.09 $20,800 - $32,288	-3,200 Reduced 20.0%	12,800 $116,000
Q1 2023 May 15, 2023	SELL	$6.01 - $10.18 $74,524 - $126,232	-12,400 Reduced 43.66%	16,000 $103,000
Q4 2022 Feb 14, 2023	SELL	$6.13 - $7.96 $3,065 - $3,980	-500 Reduced 1.73%	28,400 $180,000
Q3 2022 Nov 14, 2022	BUY	$6.04 - $10.44 $38,656 - $66,816	6,400 Added 28.44%	28,900 $179,000

5.92M

243K

46.4K

Ticker INMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,946,000
Market Cap $79.3M
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.